FY2022 EPS Estimates for AC Immune SA (NASDAQ:ACIU) Reduced by Analyst

AC Immune SA (NASDAQ:ACIUGet Rating) – SVB Leerink decreased their FY2022 earnings per share estimates for AC Immune in a report released on Monday, August 1st. SVB Leerink analyst M. Goodman now forecasts that the company will post earnings per share of ($1.05) for the year, down from their previous estimate of ($1.03). SVB Leerink has a “Outperform” rating and a $10.00 price objective on the stock. The consensus estimate for AC Immune’s current full-year earnings is ($0.99) per share. SVB Leerink also issued estimates for AC Immune’s Q4 2022 earnings at ($0.28) EPS and FY2026 earnings at ($1.10) EPS.

AC Immune (NASDAQ:ACIUGet Rating) last posted its earnings results on Thursday, July 28th. The company reported ($0.23) EPS for the quarter, beating the consensus estimate of ($0.24) by $0.01.

Several other equities research analysts have also recently weighed in on ACIU. HC Wainwright reissued a “buy” rating and issued a $16.00 price target on shares of AC Immune in a research note on Friday, June 17th. StockNews.com initiated coverage on AC Immune in a research note on Wednesday, July 27th. They issued a “sell” rating for the company.

AC Immune Price Performance

AC Immune stock opened at $3.57 on Thursday. The company has a current ratio of 13.28, a quick ratio of 13.28 and a debt-to-equity ratio of 0.01. The company has a market capitalization of $298.28 million, a PE ratio of -3.53 and a beta of 0.68. AC Immune has a 12 month low of $2.06 and a 12 month high of $12.61. The stock has a 50-day moving average price of $3.28 and a two-hundred day moving average price of $3.71.

Institutional Investors Weigh In On AC Immune

A number of hedge funds have recently added to or reduced their stakes in the company. Renaissance Technologies LLC grew its stake in AC Immune by 2.3% in the first quarter. Renaissance Technologies LLC now owns 452,490 shares of the company’s stock valued at $1,810,000 after acquiring an additional 10,300 shares during the period. Lombard Odier Asset Management Switzerland SA grew its stake in AC Immune by 9.2% in the fourth quarter. Lombard Odier Asset Management Switzerland SA now owns 348,196 shares of the company’s stock valued at $1,724,000 after acquiring an additional 29,451 shares during the period. BlackRock Inc. grew its stake in AC Immune by 1.6% in the first quarter. BlackRock Inc. now owns 292,273 shares of the company’s stock valued at $1,169,000 after acquiring an additional 4,685 shares during the period. Assenagon Asset Management S.A. acquired a new stake in AC Immune in the fourth quarter valued at approximately $730,000. Finally, Handelsbanken Fonder AB acquired a new stake in AC Immune in the first quarter valued at approximately $404,000. Institutional investors and hedge funds own 26.49% of the company’s stock.

About AC Immune

(Get Rating)

AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms are designed to generate vaccines, antibodies, and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases.

Further Reading

Earnings History and Estimates for AC Immune (NASDAQ:ACIU)

Receive News & Ratings for AC Immune Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AC Immune and related companies with MarketBeat.com's FREE daily email newsletter.